FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1529086182> ?p ?o ?g. }

• W1529086182 abstract "Background In the absence of antiretroviral therapy (ART), over 50% of HIV‐infected infants progress to AIDS and death by 2 years of age. However, there are challenges to initiation of ART in early life, including the possibility of drug resistance in the context of prevention of mother‐to‐child transmission (PMTCT) programs, a paucity of drug choices , uncertain dosing for some medications and long‐term toxicities. Key management decisions include when to start ART, what regimen to start, and whether and when to substitute drugs or interrupt therapy. This review, an update of a previous review, aims to summarize the currently available evidence on this topic and inform the ART management in HIV‐infected children less than 3 years of age. Objectives To evaluate 1) when to start ART in young children (less than 3 years); 2) what ART to start with, comparing first‐line non‐nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI)‐based regimens; and 3) whether alternative strategies should be used to optimize antiretroviral treatment in this population: induction (initiation with 4 drugs rather than 3 drugs) followed by maintenance ART, interruption of ART and substitution of PI with NNRTI drugs once virological suppression is achieved on a PI‐based regimen. Search methods Search methods We searched for published studies in the Cochrane HIV/AIDS Review Group Trials Register, The Cochrane Library, Pubmed, EMBASE and CENTRAL. We screened abstracts from relevant conference proceedings and searched for unpublished and ongoing trials in clinical trial registries (ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform). Selection criteria We identified RCTs that recruited perinatally HIV‐infected children under 3 years of age without restriction of setting. We rejected trials that did not include children less than 3 years of age, did not provide stratified outcomes for those less than 3 years or did not evaluate either timing of ART initiation, choice of drug regimen or treatment switch/interruption strategy. Data collection and analysis Two reviewers independently applied study selection criteria, assessed study quality and extracted data. Effects were assessed using the hazard ratio (HR) for time‐to‐event outcomes, relative risk for dichotomous outcomes and weighted mean difference for continuous outcomes. Main results A search of the databases identified a total of 735 unique, previously unreviewed studies, of which 731 were excluded to leave 4 new studies to incorporate into the review. Four additional studies were identified in conference proceedings, for a total of 8 studies addressing when to start treatment (n=2), what to start (n=3), whether to substitute lopinavir/ritonavir (LPV/r) with nevirapine (NVP) (n=1), whether to use an induction‐maintenance ART strategy (n=1) and whether to interrupt treatment (n=1). Treatment initiation in asymptomatic infants with good immunological status was associated with a 75% reduction (HR=0.25; 95%CI 0.12‐0.51; p=0.0002) in mortality or disease progression in the one trial with sufficient power to address this question. In a smaller pilot trial, median CD4 cell count was not significantly different between early and deferred treatment groups 12 months after ART. Regardless of previous exposure to nevirapine for PMTCT, the hazard for treatment failure at 24 weeks was 1.79 (95%CI 1.33, 2.41) times higher in children starting ART with a NVP‐based regimen compared to those starting with a LPV/r‐based regimen (p=0.0001) with no clear difference in the effect observed for children younger or older than 1 year. The hazard for virological failure at 24 weeks was overall 1.84 (95%CI 1.29, 2.63) times higher for children starting ART with a NVP‐based regimen compared to those starting with a LPV/r‐based regimen (p=0.0008) with a larger difference in time to virological failure (or death) between the NVP and LPV/r‐based regimens when ART was initiated in the first year of life. Infants starting a LPV/r regimen and achieving sustained virological suppression who then substituted LPV/r with NVP after median 9 months on LPV/r were less likely to develop virological failure (defined as at least one VL greater than 50 copies/mL) compared with infants who started and stayed on LPV/r (HR=0.62, 95%CI 0.41, 0.92, p=0.02). However the hazard for confirmed failure at a higher viral load (>1000 copies/mL) was greater among children who switched to NVP compared to those who remained on LPV/r (HR=10.19, 95% CI 2.36, 43.94, p=0.002). Children undergoing an induction‐maintenance ART approach with a 4‐drug NNRTI‐based regimen for 36 weeks, followed by 3‐drug ART, had significantly greater CD4 rise than children receiving a standard 3‐drug NNRTI‐based ART at 36 weeks (mean difference 1.70 [95%CI 0.61, 2.79] p=0.002) and significantly better viral load response at 24 weeks (OR 1.99 [95%CI 1.09, 3.62] p=0.02). However, the immunological and virological benefits were short‐term. The one trial of treatment interruption that compared children initiating continuous ART from infancy with children interrupting ART was terminated early because the duration of treatment interruption was less than 3 months in most infants. Children interrupting treatment had similar growth and occurrence of serious adverse events as those in the continuous arm. Authors' conclusions ART initiation in asymptomatic children under 1 year of age reduces morbidity and mortality, but it remains unclear whether there are clinical benefits to starting ART in asymptomatic children diagnosed with HIV infection between 1‐3 years. The available evidence shows that a LPV/r‐based first‐line regimen is more efficacious than a NVP‐based regimen, regardless of PMTCT exposure status. New formulations of LPV/r are urgently required to enable new WHO recommendations to be implemented. An alternative approach to long‐term LPV/r is substituting LPV/r with NVP once virological suppression is achieved. This strategy looked promising in the one trial undertaken, but may be difficult to implement in the absence of routine viral load testing. A 4‐drug induction‐maintenance approach showed short‐term virological and immunological benefits during the induction phase but, in the absence of sustained benefits, is not recommended as a routine treatment strategy. Treatment interruption following early ART initiation in infancy was challenging for children who were severely immunocompromised in the context of poor clinical immunological condition at ART initiation due to the short duration of interruption, and is therefore not practical in ART treatment programmes where close monitoring is not feasible." @default.
• W1529086182 created "2016-06-24" @default.
• W1529086182 creator A5006124684 @default.
• W1529086182 creator A5011349295 @default.
• W1529086182 creator A5025323660 @default.
• W1529086182 creator A5041072379 @default.
• W1529086182 creator A5058881734 @default.
• W1529086182 date "2014-05-22" @default.
• W1529086182 modified "2023-09-25" @default.
• W1529086182 title "Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age" @default.
• W1529086182 cites W1524739797 @default.
• W1529086182 cites W1558056931 @default.
• W1529086182 cites W1966166718 @default.
• W1529086182 cites W1972069251 @default.
• W1529086182 cites W1981386613 @default.
• W1529086182 cites W1983839348 @default.
• W1529086182 cites W1994604880 @default.
• W1529086182 cites W2004027480 @default.
• W1529086182 cites W2028099639 @default.
• W1529086182 cites W2039293710 @default.
• W1529086182 cites W2040113924 @default.
• W1529086182 cites W2043724397 @default.
• W1529086182 cites W2050808362 @default.
• W1529086182 cites W2056243308 @default.
• W1529086182 cites W2069856006 @default.
• W1529086182 cites W2081745197 @default.
• W1529086182 cites W2088020479 @default.
• W1529086182 cites W2089034023 @default.
• W1529086182 cites W2093979189 @default.
• W1529086182 cites W2094340292 @default.
• W1529086182 cites W2100980617 @default.
• W1529086182 cites W2102155948 @default.
• W1529086182 cites W2102834723 @default.
• W1529086182 cites W2116360856 @default.
• W1529086182 cites W2118936275 @default.
• W1529086182 cites W2122986037 @default.
• W1529086182 cites W2134746895 @default.
• W1529086182 cites W2148521133 @default.
• W1529086182 cites W2148684707 @default.
• W1529086182 cites W2167590829 @default.
• W1529086182 cites W2168039974 @default.
• W1529086182 cites W2170003531 @default.
• W1529086182 cites W2170162787 @default.
• W1529086182 cites W2170463669 @default.
• W1529086182 cites W2174240998 @default.
• W1529086182 cites W2184002906 @default.
• W1529086182 cites W2591476765 @default.
• W1529086182 doi "https://doi.org/10.1002/14651858.cd004772.pub4" @default.
• W1529086182 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24852077" @default.
• W1529086182 hasPublicationYear "2014" @default.
• W1529086182 type Work @default.
• W1529086182 sameAs 1529086182 @default.
• W1529086182 citedByCount "24" @default.
• W1529086182 countsByYear W15290861822015 @default.
• W1529086182 countsByYear W15290861822016 @default.
• W1529086182 countsByYear W15290861822017 @default.
• W1529086182 countsByYear W15290861822018 @default.
• W1529086182 countsByYear W15290861822019 @default.
• W1529086182 countsByYear W15290861822020 @default.
• W1529086182 countsByYear W15290861822021 @default.
• W1529086182 countsByYear W15290861822022 @default.
• W1529086182 crossrefType "journal-article" @default.
• W1529086182 hasAuthorship W1529086182A5006124684 @default.
• W1529086182 hasAuthorship W1529086182A5011349295 @default.
• W1529086182 hasAuthorship W1529086182A5025323660 @default.
• W1529086182 hasAuthorship W1529086182A5041072379 @default.
• W1529086182 hasAuthorship W1529086182A5058881734 @default.
• W1529086182 hasConcept C126322002 @default.
• W1529086182 hasConcept C142462285 @default.
• W1529086182 hasConcept C151730666 @default.
• W1529086182 hasConcept C168563851 @default.
• W1529086182 hasConcept C177713679 @default.
• W1529086182 hasConcept C187212893 @default.
• W1529086182 hasConcept C2776478404 @default.
• W1529086182 hasConcept C2777288759 @default.
• W1529086182 hasConcept C2779343474 @default.
• W1529086182 hasConcept C2781143361 @default.
• W1529086182 hasConcept C2781413609 @default.
• W1529086182 hasConcept C2908647359 @default.
• W1529086182 hasConcept C2993143319 @default.
• W1529086182 hasConcept C3013748606 @default.
• W1529086182 hasConcept C512399662 @default.
• W1529086182 hasConcept C535046627 @default.
• W1529086182 hasConcept C71924100 @default.
• W1529086182 hasConcept C86803240 @default.
• W1529086182 hasConcept C99454951 @default.
• W1529086182 hasConceptScore W1529086182C126322002 @default.
• W1529086182 hasConceptScore W1529086182C142462285 @default.
• W1529086182 hasConceptScore W1529086182C151730666 @default.
• W1529086182 hasConceptScore W1529086182C168563851 @default.
• W1529086182 hasConceptScore W1529086182C177713679 @default.
• W1529086182 hasConceptScore W1529086182C187212893 @default.
• W1529086182 hasConceptScore W1529086182C2776478404 @default.
• W1529086182 hasConceptScore W1529086182C2777288759 @default.
• W1529086182 hasConceptScore W1529086182C2779343474 @default.
• W1529086182 hasConceptScore W1529086182C2781143361 @default.
• W1529086182 hasConceptScore W1529086182C2781413609 @default.
• W1529086182 hasConceptScore W1529086182C2908647359 @default.
• W1529086182 hasConceptScore W1529086182C2993143319 @default.
• W1529086182 hasConceptScore W1529086182C3013748606 @default.

• next